Table 1 Baseline characteristics of the sample
From: Plasma MCP-1 and changes on cognitive function in community-dwelling older adults
Characteristics | Whole sample Total (n = 1097) | Low MCP-1 (n = 823) | High MCP-1a (n = 274) | Low Aβ42/40 (n = 137) | High Aβ42/40b (n = 292) |
|---|---|---|---|---|---|
Women, No. (%)d | 700 (63.81%) | 531 (64.52%) | 169 (61.68%) | 182 (73.09%) | 110 (61.11%) |
Age, yearsc,d | 75.30 (4.37) | 74.94 (4.21) | 76.38 (4.66) | 76.49 (4.77) | 75.40 (4.44) |
MAPT group allocation, No. (%)d | |||||
 Omega 3 + MDI group | 274 (24.98%) | 212 (25.76%) | 62 (22.63%) | 87 (29.79%) | 27 (19.71%) |
 Omega 3 group | 267 (24.34%) | 203 (24.67%) | 64 (23.36%) | 64 (21.92%) | 37 (27.01%) |
 MDI group | 277 (25.25%) | 198 (24.06%) | 79 (28.83%) | 77 (26.37%) | 27 (19.71%) |
 Control group | 279 (25.43%° | 210 (25.52%) | 69 25.18%) | 64 (21.92%) | 46 (33.58%) |
Education, No. (%)d | |||||
 No diploma | 49 (4.54%) | 37 (4.57%) | 12 (4.43%) | 4 (2.96%) | 13 (4.51%) |
 Primary school certificate | 179 (16.57%) | 133 (16.44%) | 46 (16.97%) | 38 (28.15%) | 47 (16.32%) |
 Secondary education | 354 (32.78%) | 256 (31.64%) | 98 (36.16%) | 52 (38.52%) | 84 (29.17%) |
 High school diploma | 168 (15.56%) | 135 (16.69%) | 33 (12.18%) | 10 (7.41%) | 51 (17.71%) |
 University level | 330 (30.56%) | 248 (30.66%) | 82 (30.26%) | 31 (22.96%) | 93 (32.29%) |
Body mass indexc,e | 26.21 (4.05) | 26.03 (3.95) | 26.75 (4.32) | 26.11 (3.51) | 26.58 (4.23) |
Composite cognitive scorec,f | 0.023 (0.69) | 0.05 (0.67) | −0.05 (0.75) | −0.22 (0.73) | −0.11 (0.75) |
CDR Sum of boxes, range 0–18c | 0.39 (0.59) | 0.35 (0.55) | 0.49 (0.69) | 0.53 (0.66) | 0.47 (0.67) |
CDR status, No. (%)c | |||||
 No cognitive impairment, CDR score, 0 | 580 (52.97%) | 456 (55.47%) | 124 (45.42%) | 151 (98.69%) | 86 (98.85%) |
 Mild cognitive impairment, CDR score, 0.5 | 509 (46.48%) | 362 (44.04%) | 147 (53.85%) | 2 (1.31%) | 1 (1.15%) |
 Major cognitive impairment, CDR score, ≥ 1 | 6 (0.55%) | 4 (0.49%) | 2 (0.73%) | 0 (0%) | 0 (0%) |
MMSE score, range 0–30 | 28.07 (1.81) | 28.10 (1.74) | 27.98 (2.01) | 27.61 (1.88) | 27.92 (1.92) |
FCSRT free recall, range 0–48c,d | 30.38 (7.52) | 30.77 (7.17) | 29.23 (8.39) | 27.54 (8.42) | 29.25 (7.86) |
FCSRT total recall, range 0–48 | 45.72 (3.80) | 45.83 (3.56) | 45.40 (4.42) | 44.45 (4.85) | 45.38 (4.71) |
FCSRT free delayed recall, range 0–16 | 11.48 (2.99) | 11.53 (2.90) | 11.33 (3.26) | 10.47 (3.48) | 10.95 (3.08) |
FCSRT total delayed recall, range 0–16 | 15.52 (1.25) | 15.53 (1.22) | 15.46 (1.33) | 15.19 (1.55) | 15.37 (1.58) |
APOE ε4 genotype, No. (%)d | |||||
 APOE ε4 carriers | 226 (22.89%) | 168 (20.4%) | 58 (21.2%) | 45 (33.83%) | 58 (22.83%) |
 Non-APOE ε4 carriers | 761 (77.11%) | 572 (79.6%) | 189 (79.8%) | 88 (66.17%) | 196 (77.17%) |